You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Pathophysiology/Complications
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

 

Online download statistics by month:

Online download statistics by month: July 2017 to September 2024

AbstractFullPdf
Jul 201715915555
Aug 2017216208134
Sep 201710210051
Oct 2017838237
Nov 2017707024
Dec 2017848427
Jan 2018747414
Feb 2018756816
Mar 201812011832
Apr 2018696916
May 2018646821
Jun 2018808225
Jul 2018595916
Aug 2018403815
Sep 2018353516
Oct 2018363520
Nov 201810910912
Dec 201816416417
Jan 201912612715
Feb 201913113210
Mar 2019696622
Apr 2019363311
May 2019302617
Jun 2019262626
Jul 2019383630
Aug 2019292915
Sep 2019262611
Oct 2019262413
Nov 2019343014
Dec 2019333317
Jan 2020262521
Feb 2020333112
Mar 2020242314
Apr 2020181711
May 2020262624
Jun 2020151511
Jul 2020181810
Aug 2020141316
Sep 2020333128
Oct 2020505013
Nov 202014149
Dec 2020211817
Jan 2021242010
Feb 2021141317
Mar 2021222111
Apr 202118173
May 202152516
Jun 202142388
Jul 2021323014
Aug 202117164
Sep 202118174
Oct 2021242128
Nov 2021242218
Dec 202123226
Jan 202215143
Feb 2022211913
Mar 202243449
Apr 202260595
May 202217176
Jun 202216146
Jul 202223222
Aug 202214128
Sep 2022292736
Oct 2022292711
Nov 2022211911
Dec 2022222212
Jan 202329258
Feb 202332312
Mar 202314133
Apr 20231094
May 2023334
Jul 2023876
Aug 2023765
Sep 202319155
Oct 202312125
Nov 202317152
Dec 202364585
Jan 202411109
Feb 202416139
Mar 20248711
Apr 202424205
May 2024532
Jun 2024662
Jul 20241084
Aug 2024874
Sep 202412116
Total347033501287